Apple Health App Integrates MightySat Data
IRVINE, Calif.--(BUSINESS WIRE)--Sep. 6, 2016--
Masimo (NASDAQ:
MASI) announced today that MightySat™, a fingertip pulse oximeter
designed for general wellness and health applications including sports,
fitness, and relaxation management, is now available at Apple.com
and select
Apple retail stores in the US and Canada.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160906005766/en/
Masimo MightySat and Personal Health App (Photo: Business Wire)
Masimo pulse oximeters, the leading brand in hospitals, provide accurate
measurements when other pulse oximeters fail. By using a revolutionary
invention called Signal Extraction Technology® (SET®),
which allows oxygen saturation and pulse rate to be measured through
challenging conditions including movement and low blood flow, the same
high performance Masimo SET® technology used in hospitals is
now available to Apple customers with MightySat.
The MightySat provides the following noninvasive measurements:
-
Oxygen Saturation (SpO2)
-
Pulse Rate (PR)
-
Perfusion Index (PI)
In a study of 70 healthy volunteers during conditions of movement and
low blood flow, Masimo SET® was the most accurate pulse
oximeter when compared to 19 other hospital-grade pulse oximeters.1
SpO2 accuracy was defined as being within 7% of the reference
value and pulse rate accuracy as being within 10%. Masimo SET®
SpO2 was accurate 94% of the time while on average, the 19
other hospital-grade pulse oximeters were accurate only 60% of the time,
with the least accurate only displaying accurate SpO2 27% of
the time. Masimo SET® pulse rate was accurate 85% of the time
while on average, the 19 other hospital-grade pulse oximeters were
accurate only 27% of the time, with the least accurate only displaying
accurate pulse rate 5% of the time.
Leading athletes and sports teams are increasingly using MightySat. “The
reliable measurements of oxygen saturation and pulse rate from Masimo
pulse oximeters were an important part of my training and recovery
regimen to achieve peak athletic performance,” said Dotsie Bausch, 2012
Olympic medalist in cycling. “I trust MightySat to accurately track and
trend my data on a daily basis and help me achieve optimal health,
wellness, and fitness.”
MightySat users can display and track their data on a compatible iOS®
device via the free Masimo Personal Health app available in the App
Store. With user permission MightySat securely stores and trends
measurements displayed in the Masimo Personal Health app in Apple’s
Health app. With the most recent update, the Masimo Personal Health app
also now features same-screen trending for all MightySat measurements.
@MasimoPersonalHealth |
#MightySat
The MightySat fingertip pulse oximeter is intended for general wellness
and health applications. For medical applications, Masimo offers the
MightySat Rx, which is available to medical professionals.
Reference
-
Barker S.J. Anesth Analg. 2002 Oct;95(4):967-72.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo MightySat™. These forward-looking statements are
based on current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our
actual results to differ materially and adversely from those expressed
in our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our expectations
regarding how retail customers will react to and benefit from the Masimo
MightySat; risks related to our assumptions regarding the repeatability
of study results; risks related to our belief that Masimo's unique
noninvasive measurement technologies, including Masimo MightySat,
contribute to positive outcomes; as well as other factors discussed in
the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906005766/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com